Biotech News

GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

GH Research (GHRS)GH ResearchCompany update

Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPD Brings more than 20 years of global pharmaceutical R&D experience at Johnson & Johnson across clinical operations, clinical development, regulatory strategy, and neuroscience

Related news

GH Research

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals...

Recent company news

Stock data

Close
18.56 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States